| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year | Frank Vinluan | 04/14/20 | National |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month | Frank Vinluan | 04/09/20 | National |
| Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment | Editors | 04/06/20 | Boston |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| Flagship Adds $1.1B for New Meds, More AI, & “Health Security” | Sarah de Crescenzo | 04/02/20 | National |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel | Sarah de Crescenzo | 03/26/20 | Boston |
| CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas | Frank Vinluan | 03/24/20 | San Francisco |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
| Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More | Sarah de Crescenzo | 03/20/20 | National |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug | Sarah de Crescenzo | 03/11/20 | Seattle |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK | Frank Vinluan | 02/27/20 | New York |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More | Sarah de Crescenzo | 02/21/20 | National |
| SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal | Sarah de Crescenzo | 02/20/20 | Seattle |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| BIO Report: More Work Needed to Improve Diversity at Biotech Firms | Sarah de Crescenzo | 01/30/20 | National |
| BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely | Sarah de Crescenzo | 01/28/20 | Boulder/Denver |
